4 September 2020 - CSL Behring a global biotherapeutics leader announced today that the company will host a symposium focused on the challenges of treating lung disease in the midst of the global COVID-19 pandemic.
The symposium will take place on Monday, 7 September at 13:15 –14:15 (CEST) as part of the 30th International Congress of the European Respiratory Society (ERS). Co-chairs Tobias Welte, MD, PhD, Timm Greulich, MD, PhD and Marco Idzko, MD, PhD will lead discussions on:
- Challenges of Treating Lung Disease Caused by COVID-19
- Treatment of Alpha1 Antitrypsin Deficiency in Times of COVID-19
- Impact of Alpha1 Antitrypsin Deficiency Therapy on Mortality
- Development of Specialised Treatments for Severe Respiratory Conditions
“We are all experiencing the impact of COVID-19,” said Professor Tobias Welte, Head of the Department of Pulmonary and Infectious Diseases at Hanover University School of Medicine. “This symposium aims to address some of the challenges it brings to healthcare professionals specialised in Alpha 1, as well as to discuss new potential therapeutic options from CSL Behring related to COVID-19, severe asthma and non-cystic fibrosis bronchiectasis (NCFB).
In addition to the symposium, the company also launched the “Walk for Alpha 1”, for which participants were able to log steps that counted towards a donation to the patient organisation Team Alpha-1 Athlete. With CSL Behring donating 10 € for every 1000th step (up to 2 million steps) to Team Alpha-1 Athlete, numerous participants across 10 countries have exceeded the target, with a total of about 3.5 million steps, or 2,700 kilometres. This fantastic achievement will now allow Team Alpha-1 Athlete to raise further awareness of Alpha 1 Antitrypsin Deficiency and encapsulates one of CSL Behring’s key values: our commitment and promise to patients.
“CSL Behring has always been driven by a promise to our patients and this year that promise is stronger than ever,” said Heike Thiele, Executive Director, Respiratory Therapeutic Area, Global Commercial Development, CSL Behring. “Our ERS presence is designed to support healthcare professionals with information about treating Alpha 1 patients during this pandemic and, having recently created a Therapeutic Area Respiratory, to inform them about our exciting new drug development projects in Respiratory.”
CSL Behring will also host a virtual booth, where visitors can obtain information and pose questions to CSL Behring.
On Wednesday, 9 September, from 14:30 to 15:30 (CEST) a scientific session will discuss “Challenging clinical Cases: Airway diseases”. In line with CSL Behring’s company value of focusing on patients, Professor Balbi will present a patient case illustrating the importance of early awareness and establishing a collaborative approach to patient care, as well as the initiation of intensive treatment in Alpha 1 Antitrypsin Deficiency.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.
# # #
Mobile: +49 171 943 95 69